Preparation and administration form comprising an acid-labile active compound
View Patent ↗Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.
1. An oral solid active compound unit comprising a solidified drop, the solidified drop comprising:
a matrix comprising a mixture of cetyl palmitate or at least one triglyceride selected from the group consisting of tristearate, tripalmitate and trimyristate, and at least one solid paraffin; and
an acid-labile active compound selected from the group consisting of substituted pyridin-2-yl-methylsulfinyl-1H-benzimidazoles, substituted phenylmethylsulfinyl-1H-benzimidazoles, substituted cycloheptapyridin-9-ylsulfinyl-1H-benzimidazoles and substituted pyridin-2-ylmethylsulfinyl-thienoimidazoles, wherein said acid-labile active compound is present in said matrix, and wherein the solidified drop does not comprise an enteric coating.
2. The oral solid active compound unit as claimed in claim 1 , wherein the matrix further comprises one or more excipients selected from the group consisting of polymers, sterols and basic compounds.
3. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is selected from the group consisting of omeprazole, pantoprazole, lansoprazole and rabeprazole.
4. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is pantoprazole sodium sesquihydrate, (−)-pantoprazole sodium sesquihydrate, omeprazole magnesium, omeprazole, esomeprazole magnesium or esomeprazole.
5. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is pure enantiomer.
6. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is esomeprazole or (−)-pantoprazole.
7. The oral solid active compound unit as claimed in claim 1 , wherein the solidified drop has a particle size range of 50-800 μm.
8. The oral solid active compound unit as claimed in claim 1 , wherein the solidified drop has a particle size range of 50-400 μm.
9. The oral solid active compound unit as claimed in claim 1 , wherein the solidified drop has a particle size range of 50-200 μm.
10. The oral solid active compound unit as claimed in claim 1 , wherein the solid paraffin is paraffinum solidum or ozocerite.
11. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is 1-90% by weight of the oral solid active compound unit.
12. The oral solid active compound unit as claimed in claim 11 , wherein the acid-labile active compound is 2-70% by weight of the oral solid active compound unit.
13. The oral solid active compound unit as claimed in claim 11 , wherein the acid-labile active compound is 5-40% by weight of the oral solid active compound unit.
14. The oral solid active compound unit as claimed in claim 11 , wherein the acid-labile active compound is 10-20% by weight of the oral solid active compound unit.
15. The oral solid active compound unit as claimed in claim 1 , wherein the solid paraffin is 10-70% by weight of the oral solid active compound unit.
16. The oral solid active compound unit as claimed in claim 15 , wherein the solid paraffin is 30-60% by weight of the oral solid active compound unit.
17. The oral solid active compound unit as claimed in claim 15 , wherein the solid paraffin is 20-60% by weight of the oral solid active compound unit.
18. The oral solid active compound unit as claimed in claim 1 , wherein the acid-labile active compound is selected from the group consisting of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl)-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: lansoprazole), 2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]-methylsulfinyl)-1H-benzimidazole (INN: rabeprazole), 2-[2-(N-isobutyl-N-methylamino)benzylsulfinyl]benzimidazole (INN: leminoprazole), 2-(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta-[b]-pyridin-9-ylsulfinyl)-1H-benzimidazole (INN: nepaprazole), 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (INN: esomeprazole), (−)-pantoprazole, pantoprazole sodium sesquihydrate, (−)-pantoprazole sodium sesquihydrate, omeprazole magnesium, omeprazole, esomeprazole magnesium and esomeprazole.